LifeCodexx, a subsidiary of German sequencing service provider GATC Biotech, plans to launch its non-invasive prenatal trisomy 21 test, called LifeCodexx PraenaTest, in the second quarter of this year, the company said this week.
The firm has obtained more than 500 blood samples for its ongoing prospective blinded clinical study, which is comparing the test with conventional invasive testing methods.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
